Latest / What's Your Problem? / Can We Slow Down Aging?
Transcript
- 0:15Speaker 1: Pushkin. I'm Jacob Goldstein, and this is what's your problem.
- 0:33Speaker 1: My guest today is Near Barzilai. Near is a physician
- 0:37Speaker 1: and a researcher, and he runs the Institute for Gero
- 0:41Speaker 1: Science at the Albert Einstein College of Medicine in New York.
- 0:45Speaker 1: Near's problem is this, how can lifestyle changes and drugs
- 0:49Speaker 1: slow the process of aging. In our conversation, Nier and
- 0:53Speaker 1: I talk about the search for biological markers of aging,
- 0:57Speaker 1: existing drugs that might reduce the risk of diseases associated
- 1:02Speaker 1: with aging, and what he learned by studying the genes
- 1:05Speaker 1: of people who lived to age one hundred and beyond. Also,
- 1:09Speaker 1: we talk about the meaning and origin of the term
- 1:12Speaker 1: gyo science. To start, I asked her how he decided
- 1:16Speaker 1: to study the biology of aging.
- 1:18Speaker 2: It actually happened young. It happened with my grandfather that
- 1:22Speaker 2: walked with me every Saturday telling me about his life
- 1:27Speaker 2: as a young person. And he was sixty eight. It's
- 1:30Speaker 2: the year he died. He was looking old, fat, slow,
- 1:37Speaker 2: and for me it always it almost became immediately clear
- 1:44Speaker 2: that that's where I'm going, Okay, So it became the
- 1:48Speaker 2: biggest question in biology of aging. When I went to
- 1:53Speaker 2: my residency. I had an attending and whenever I presented
- 1:58Speaker 2: the patient, he would stop me. I would say, this
- 2:02Speaker 2: is a seventy five year old woman, and he would
- 2:05Speaker 2: stop and say, but does she look younger than their age?
- 2:11Speaker 2: And after a while you saw that it mattered. You
- 2:14Speaker 2: can have a ninety year old guy and it comes
- 2:16Speaker 2: to the emergency room and he has some infection and
- 2:18Speaker 2: with some antibiotics, he'll be fine, and a seventy five
- 2:21Speaker 2: year old woman that all her systems are totally gone,
- 2:24Speaker 2: and you know, you know where she's going, and that
- 2:28Speaker 2: it's important in decision making. I want to say that
- 2:35Speaker 2: this is thing that I think people intuitively understand that
- 2:39Speaker 2: there's a biological age. I think it's more important to
- 2:43Speaker 2: know that aging, this biology is what drives diseases. It's
- 2:50Speaker 2: not that we get heart attacks and we become old.
- 2:53Speaker 2: It's the opposite. We become old and that drives diseases.
- 2:57Speaker 1: I mean, intuitively, we also know that, right you're much
- 3:01Speaker 1: more likely to get a heart attack at seventy five
- 3:03Speaker 1: than at twenty five.
- 3:05Speaker 2: That's true, but let me give an example that you'll
- 3:08Speaker 2: explain it better. You can be born with genes for Alzheimer's. Okay,
- 3:13Speaker 2: there's a gene called apo E four. If you have
- 3:17Speaker 2: two copies of these genes, you are really high risk
- 3:21Speaker 2: of getting alzheimer at sixty or seventy and you'll be
- 3:24Speaker 2: dead by the time you're eighteen. But when you're born,
- 3:28Speaker 2: you're not demented. And when you're one year or ten
- 3:31Speaker 2: year of fifty year, you're not demented. You meet the
- 3:34Speaker 2: biology of aging, the failure of our young biology in
- 3:39Speaker 2: order to get those diseases. And it's important because we
- 3:44Speaker 2: want to prevent your aging. And this is really the
- 3:48Speaker 2: biggest issue that we're talking about.
- 3:51Speaker 1: Now, tell me a little bit more about that.
- 3:54Speaker 2: So it's based on the fact that around the world
- 3:57Speaker 2: in the last few decades, we not only went from
- 4:01Speaker 2: hoping that there is something we can do, but we
- 4:04Speaker 2: actually have a promise and we're at the stage of
- 4:07Speaker 2: realizing a promise. And the promise is in what lifestyle
- 4:14Speaker 2: decisions we make, what drugs are available right now to
- 4:18Speaker 2: stunt aging, and the drugs that are being developed now
- 4:22Speaker 2: and are going to make bigger impact.
- 4:26Speaker 1: Well, so okay, so let's get into it. So here's
- 4:28Speaker 1: the three that I know. I feel like the big
- 4:31Speaker 1: three in terms of what you're talking about, exercise, sleep, well,
- 4:40Speaker 1: have friends, don't smoke, and eat whole fresh foods. That
- 4:46Speaker 1: wasn't three, I know, I thought of two more in
- 4:49Speaker 1: the middle.
- 4:50Speaker 2: So what you don't do is okay, you know, don't smoke.
- 4:56Speaker 2: There are four that every one in our field and
- 5:01Speaker 2: the longevity doctors and everyone would agree on. And that's exercise,
- 5:07Speaker 2: its diet, sleep, and it's yeah, social connectivity. Okay. Each
- 5:13Speaker 2: one of those have underlying biology of aging, and each
- 5:18Speaker 2: one of them is really important when you're young or
- 5:22Speaker 2: old to optimize. Okay, we used to say maximize, but optimize.
- 5:28Speaker 1: So those are the ones that we sort of all know,
- 5:32Speaker 1: right Whether we do them or not is a different question,
- 5:34Speaker 1: because whose we all lots of people know that those
- 5:39Speaker 1: things are good, and it is remarkable how good they are, right, Like,
- 5:43Speaker 1: exercise is so good for so many things in non
- 5:46Speaker 1: obvious ways. Like sure, cardiovascular exercise is good for your heart,
- 5:50Speaker 1: that's obvious, but like, why does it make you less
- 5:53Speaker 1: likely to get cancer? This is an interesting question, right, Hey.
- 5:56Speaker 2: I just answer that because those are affecting the biology
- 6:00Speaker 2: of aging a bold claim. Those are affecting the biology
- 6:05Speaker 2: of aging, and when I'm talking of biology of aging
- 6:09Speaker 2: is cellular aging. So cells all over the body will
- 6:14Speaker 2: will be younger or stay younger, and that's why you
- 6:18Speaker 2: get less cancer and less and less cardiovastro disease.
- 6:23Speaker 1: When you say cellular age, what is the measure of
- 6:26Speaker 1: cellular age you're referring to?
- 6:29Speaker 2: Let me say this way. There are twelve things that
- 6:34Speaker 2: we call hallmarks of aging. Okay, and I'm not going
- 6:37Speaker 2: to count them. I might give an example throughout.
- 6:40Speaker 1: Give me one example. What's the what's a particularly robust example.
- 6:44Speaker 2: Let's say that one of the problems is we have
- 6:48Speaker 2: a mechanism of garbage disposal in all our cells. And
- 6:54Speaker 2: this garbage disposal that's often called autophogy, or the scientists
- 6:58Speaker 2: will call it autophogy, takes junks that accumulate in our
- 7:03Speaker 2: cells because our selves is making mistakes in its production.
- 7:07Speaker 2: And it's taking those things that are really not helpful
- 7:11Speaker 2: and breaking them down to their component. It's going to
- 7:15Speaker 2: clean yoursels. Okay, Okay, that's what's going to happen now
- 7:20Speaker 2: every one of the hallmarks. What you have to show
- 7:23Speaker 2: is first of all, that it gets worse with aging. Second,
- 7:27Speaker 2: you can take a young model and make it old. Okay,
- 7:31Speaker 2: so it was done with autopogy. You knock out autophogy,
- 7:35Speaker 2: the mice are freaking out. They are becoming older at
- 7:39Speaker 2: a very young age. But more important, if you fix
- 7:42Speaker 2: it throughout aging, the mice are not only healthier overall healthier,
- 7:48Speaker 2: but they also live like twenty percent longer. Okay, So
- 7:52Speaker 2: that's how you become a hallmark. But the point is,
- 7:55Speaker 2: whenever you fix one of them, of those hallmarks, you
- 8:00Speaker 2: really fix also others. Okay. So it's you could take
- 8:05Speaker 2: one hallmark and show that it's very important, but you
- 8:07Speaker 2: can do it with each one of them. You don't
- 8:09Speaker 2: have to do it together. Not that doing it together
- 8:12Speaker 2: wouldn't be even better, but you don't have to do
- 8:15Speaker 2: it together.
- 8:15Speaker 1: You're saying, if you fix one, that one working better
- 8:18Speaker 1: actually helps to fix the others, right.
- 8:21Speaker 2: And you can see changes in the others.
- 8:23Speaker 1: And so when you talk about these, you know lifestyle
- 8:29Speaker 1: changes like exercise, does your autophogy work better for longer?
- 8:36Speaker 1: That basically going.
- 8:37Speaker 2: On exactly, And I'll give you another example. And I
- 8:41Speaker 2: can stay on autopogy because we don't have enough time
- 8:45Speaker 2: to cover the twelve. But how does so exercise fixes autophogy.
- 8:53Speaker 2: The hard one is diet. And I'll tell you why
- 8:56Speaker 2: I pick diet, because diet is something that's very individual.
- 9:01Speaker 2: It's it's it's really you know, if I take people
- 9:05Speaker 2: and say you should become vegetarians, they're going to which
- 9:09Speaker 2: proteins with carbohydrates, They're going to get fat or some
- 9:12Speaker 2: of them, and they're going to actually pay. Their health
- 9:16Speaker 2: is going to be worse. So it's very in the individual.
- 9:20Speaker 2: How do you choose diet and how you can actually
- 9:23Speaker 2: stick to a diet. So when I started my studies,
- 9:29Speaker 2: the experiment that worked in every lab, I took rats
- 9:33Speaker 2: and half of them got to eat whatever they wanted
- 9:37Speaker 2: and the other half I gave them forty percent less
- 9:40Speaker 2: food forty percent less food, so sixty percent of what
- 9:44Speaker 2: the others got. The rats that got sixty percent of
- 9:49Speaker 2: the food lived healthier and lived longer. What we did
- 9:54Speaker 2: is we gave the food in the morning to those animals,
- 9:57Speaker 2: and they were hungry, and they ate the food, and
- 10:00Speaker 2: they were then fasting for twenty three more hours. So
- 10:04Speaker 2: it wasn't only caloric restriction, it was also fasting. In fact,
- 10:09Speaker 2: when we gave them the food little bit throughout the day,
- 10:13Speaker 2: they were leaner, but they didn't live much longer, and
- 10:16Speaker 2: that led to this concept that a lot of us
- 10:19Speaker 2: are doing, including myself, which is intermittent fasting fast as
- 10:24Speaker 2: many hours as you can. Because what it does almost
- 10:29Speaker 2: the major thing that happened, it improves atophagy. This is
- 10:34Speaker 2: easy for most people to do, not for everyone. It's
- 10:37Speaker 2: easy for most people to do, and we don't know
- 10:40Speaker 2: if it extends life, but it certainly improves several factors
- 10:44Speaker 2: that you can look at, such as weight or metabolism
- 10:49Speaker 2: and other things.
- 10:50Speaker 1: So we're talking at nine point thirty in the morning.
- 10:53Speaker 1: When was the last time you ate?
- 10:56Speaker 2: I actually finished dinner at six pm yesterday because I
- 11:00Speaker 2: was traveling.
- 11:01Speaker 1: What's your usual?
- 11:03Speaker 2: It's usually eight in the evening when I finished dinner,
- 11:06Speaker 2: which brings me to noontime the next day. And what
- 11:10Speaker 2: I'm having. I'm having black coffee and I'm having you know, water,
- 11:14Speaker 2: but I'm not eating anything.
- 11:16Speaker 1: How do you feel right now it's been fifteen hours
- 11:18Speaker 1: since you've eaten. How do you feel?
- 11:19Speaker 2: I'll tell you the opposite. I was in Europe for
- 11:24Speaker 2: two weeks and sometimes I had breakfast, and in the
- 11:27Speaker 2: days that I had breakfast, I was just miserable, but
- 11:32Speaker 2: by noontime this is really and people in particular people
- 11:37Speaker 2: my age will tell you that they feel the benefit
- 11:40Speaker 2: on their basically cognition, their tiredness, their energy throughout the day.
- 11:48Speaker 1: So you mentioned rats and fasting, and you mentioned mice
- 11:53Speaker 1: and autophogy, and you know there is that famous line
- 11:57Speaker 1: mice lie and primates exaggerate, Like to what extent have
- 12:01Speaker 1: these studies been validated in humans?
- 12:04Speaker 2: I got a grant from our page together with Dan
- 12:07Speaker 2: Belski from Colombia.
- 12:09Speaker 1: Our pages. The government basically it.
- 12:10Speaker 2: Is the government right, and the government totally bought into
- 12:15Speaker 2: targeting aging and health spin but they funded us for
- 12:20Speaker 2: a simple reason. There are four drugs probably more that
- 12:25Speaker 2: we know target aging. And when you put those drugs
- 12:30Speaker 2: on cells, okay, they change the hallmarks of aging utophagy, Okay,
- 12:36Speaker 2: when you give them to animals, they live healthier and longer.
- 12:40Speaker 2: And in clinical studies, although those drugs were designed for
- 12:43Speaker 2: a certain disease, they also prevent other diseases. And although
- 12:49Speaker 2: they were developed for a certain disease, they prevented overall
- 12:53Speaker 2: mortality and not the disease specific mortality. So we take
- 12:57Speaker 2: studies that were already ended, and we're asking a simple question,
- 13:02Speaker 2: not only what are the biomarkers of aging, but which
- 13:06Speaker 2: one are changing with intervention?
- 13:09Speaker 1: So what exactly is the study that you're doing.
- 13:13Speaker 2: We we take blood samples that already exist because the
- 13:18Speaker 2: trials are done of four drugs, and we're looking at
- 13:23Speaker 2: what happened to each individual, whether he was on a
- 13:26Speaker 2: drug or on a placebol within the first year of therapy.
- 13:30Speaker 1: And to be clear, when you say drugs blood samples,
- 13:32Speaker 1: do you mean the actual blood or you just mean
- 13:34Speaker 1: the tests that were done on those samples in previous tests.
- 13:37Speaker 2: No, no, no, no, we have to do it's it's
- 13:39Speaker 2: totally new. We're taking the blood and using.
- 13:44Speaker 1: So people store the blood from trials. These are trials
- 13:46Speaker 1: that are years old and the blood has just been
- 13:48Speaker 1: sitting there in the fridge waiting for you to come
- 13:50Speaker 1: in the free the freezer. Yeah, of course, and so
- 13:54Speaker 1: so and and the drugs are what theyre It's met foreman, rapamycin,
- 13:59Speaker 1: GLP one, some GLP one drug.
- 14:02Speaker 2: And s GILT two inhebitors.
- 14:04Speaker 1: What's that last one. I don't know what that last
- 14:06Speaker 1: one is.
- 14:07Speaker 2: This is a very potent drug against aging. It's developed
- 14:11Speaker 2: for diabetes for sigia in volcana are the common name.
- 14:15Speaker 2: There are five five manufactures of this drug.
- 14:19Speaker 1: So there's the blood in the freezer and you're taking
- 14:21Speaker 1: it out of the freezer and you're looking at these
- 14:23Speaker 1: twelve different hallmarks of aging and you're seeing how they
- 14:26Speaker 1: change over the course of the year and comparing those
- 14:28Speaker 1: changes for people in the drug arm of these trials,
- 14:33Speaker 1: in the treatment arm versus the people in the placebo arm.
- 14:36Speaker 2: So for each individual before and after treatment, we're going
- 14:40Speaker 2: to have tons of data and we're going with AI
- 14:44Speaker 2: to reduce it to what is common for all those drugs,
- 14:49Speaker 2: what has commonly changed with treatment between all those drugs,
- 14:54Speaker 2: and this is likely to get to give us the
- 14:56Speaker 2: best clock to use in a clinical practice.
- 15:02Speaker 1: And so basically, you want to find something that is
- 15:06Speaker 1: easy to measure or relatively easy to measure from a
- 15:10Speaker 1: blood test, say so that you can look in a
- 15:12Speaker 1: blood test and ideally find someone's biological age so to speak.
- 15:18Speaker 2: Correct Again, we can do the biological age quite good now,
- 15:23Speaker 2: but what is change what has change when you actually
- 15:27Speaker 2: give a treatment that targets the age, that's the major point.
- 15:32Speaker 1: But you're assuming that bigs into that assumption is that
- 15:37Speaker 1: all these drugs in fact slow aging. That like, that
- 15:40Speaker 1: is a conclusion that has to be true for this
- 15:43Speaker 1: study to make sense. Is that right?
- 15:45Speaker 2: Well, it's the other way around. Those drugs did four
- 15:48Speaker 2: things right, each one of them. You put them in cells,
- 15:52Speaker 2: They make the cells younger. You give them to animal,
- 15:55Speaker 2: they live healthier and longer. You gave them already to people.
- 15:59Speaker 2: Those are our studies that had outcomes, and you show
- 16:03Speaker 2: that you give it for one thing and you prevented
- 16:06Speaker 2: other things, and that it changed overall mortality.
- 16:10Speaker 1: That last part is that unambiguous. Like I wish I
- 16:13Speaker 1: knew the data better.
- 16:14Speaker 2: Oh, like the studies, I mean, it's absolutely amazing. Let
- 16:18Speaker 2: me give you a flavor for the drug that you
- 16:21Speaker 2: didn't hear about as Gilty two inhibitors. S. GILTY two
- 16:25Speaker 2: inhibitors were developed for diabetes, and in the diabetes trial
- 16:29Speaker 2: it became apparent that they prevent cardiovas to disease and
- 16:33Speaker 2: kidney disease. Yeah, but then nephrologies came and did a
- 16:37Speaker 2: study and just to give you a taste, they took
- 16:40Speaker 2: four thousand people, half of them are placible and in
- 16:44Speaker 2: forty two non diabetic just people with impaired kidney function,
- 16:49Speaker 2: and in thirty two months they showed that they prevented
- 16:53Speaker 2: forty percent of deteriorating of kidney function, forty percent decrease
- 16:57Speaker 2: in cardiovas to disease, and forty percent decrease in overall mortality.
- 17:01Speaker 2: So it's circular. But what other explanation do you have
- 17:05Speaker 2: for a drug that actually changed the hallworks of agyp.
- 17:12Speaker 1: We'll be back in just a minute. Shall we talk
- 17:26Speaker 1: about your genetics work?
- 17:28Speaker 2: Sure?
- 17:30Speaker 1: What have you learned from studying the genes of people
- 17:33Speaker 1: who live to one hundred?
- 17:35Speaker 2: So first of all, I want to tell you that
- 17:38Speaker 2: my fear when I did the study was what if
- 17:42Speaker 2: I find that all those hundred years old have gotten
- 17:47Speaker 2: disease like everyone after the age of sixty, they got
- 17:51Speaker 2: disease and just lived longer with diseases. And what we
- 17:56Speaker 2: found is that they live twenty thirty years healthier. So
- 18:03Speaker 2: it's not only they lived longer, they live healthier, and
- 18:06Speaker 2: that wasn't really the big thing. The big thing is
- 18:09Speaker 2: that they had what we call a contraction of morbidity.
- 18:12Speaker 2: They will sick very little time at the end of
- 18:14Speaker 2: their lives. The CDC may rest in peace or be
- 18:18Speaker 2: resurrected whatever. The CDC have shown since nineteen ninety three
- 18:25Speaker 2: that people who die over the age of one hundred
- 18:28Speaker 2: have third of the medical cost in the last two
- 18:31Speaker 2: years of their own Interesting, then people who die at seven.
- 18:35Speaker 1: So they die, they live a long time, and then
- 18:37Speaker 1: they die fast. That's the dream exactly.
- 18:40Speaker 2: So that's what we want.
- 18:42Speaker 1: Right, that's good news for people with the genes that
- 18:45Speaker 1: cause you to live a long time. Regarding your genetic studies,
- 18:49Speaker 1: I mean, is there any I don't know people in
- 18:54Speaker 1: my family don't live to one hundred, Like, am I screwed?
- 18:57Speaker 1: Does that matter for me that study?
- 18:59Speaker 2: No, the opposite. You're the one who's going to benefit.
- 19:03Speaker 2: We don't have anything for those hundred years old, Okay,
- 19:06Speaker 2: because that's it. So two of those genes have already
- 19:10Speaker 2: been developed to drugs that past phase three trial.
- 19:14Speaker 1: That that past phase three meaning the FDA is they're
- 19:17Speaker 1: up for approval at the FDA, right, Yeah, tell me
- 19:20Speaker 1: about those drugs.
- 19:21Speaker 2: So one drug is called the CDP INHIBITORQUE. It's a
- 19:27Speaker 2: drug that basically increase your good cholesterol and decrease your
- 19:32Speaker 2: trigue glycerides. But that's only part of what it's doing.
- 19:36Speaker 1: And so when they're doing a phase three trial of
- 19:39Speaker 1: this drug, what is the end point? What are they
- 19:41Speaker 1: actually trying to show that it does?
- 19:43Speaker 2: So they're not doing it for aging. They came to
- 19:47Speaker 2: me because my studies showed that probably inhibiting CDP safe
- 19:53Speaker 2: because they are one hundred years old. Fourteen percent of
- 19:56Speaker 2: one hundred years old have these genes that increase their.
- 19:59Speaker 1: As opposed to how many people in the population.
- 20:01Speaker 2: At large three to four percent.
- 20:03Speaker 1: Okay, so it's like four times as common or something. Right,
- 20:07Speaker 1: Is that drug being developed as a cardiovascular drug? Like,
- 20:11Speaker 1: what are they testing it for?
- 20:12Speaker 2: It's been developed as a cardiovas or drug, but there's
- 20:16Speaker 2: evidence that it's also prevent cognitive decline, which was our
- 20:21Speaker 2: major claim around these drug.
- 20:24Speaker 1: Are they testing it for that? That's a hard indication
- 20:26Speaker 1: to get.
- 20:26Speaker 2: Yeah, yeah, they tested and their data.
- 20:29Speaker 1: So you've talked about these promising drugs, most of which
- 20:33Speaker 1: are approved by the FDA for something met Foreman's approved
- 20:37Speaker 1: for diabetes, GLP one drugs are approved for weight loss.
- 20:41Speaker 1: I know that you've talked in the past about getting
- 20:43Speaker 1: a broader FDA approval. Specifically, you were trying to get
- 20:47Speaker 1: funding for this study called the tame trial where you
- 20:51Speaker 1: randomize people to get met foreman or placebo, and then
- 20:54Speaker 1: the idea was you would follow them for several years
- 20:57Speaker 1: and see if the people getting met foreman had a
- 21:00Speaker 1: lower rate of things like cardiovascular disease and cancer and
- 21:03Speaker 1: overall mortality, just do they die less. So is the
- 21:07Speaker 1: idea that if you do that study and you have
- 21:10Speaker 1: a positive outcome, like, what would the FDA say, what
- 21:14Speaker 1: would the indication be? Would it be give metform into
- 21:17Speaker 1: everybody over a certain age or what?
- 21:22Speaker 2: No? No, the answer is no, because the study population
- 21:27Speaker 2: are people over the age of sixty five that are
- 21:30Speaker 2: already not doing not doing well. Not that people will
- 21:35Speaker 2: become centenarians.
- 21:37Speaker 1: Okay, uh, because you need I mean for the study
- 21:39Speaker 1: to work, you need some people to get sick. Frankly,
- 21:42Speaker 1: if everybody on both sides stays healthy, you don't learn
- 21:45Speaker 1: anything exactly.
- 21:46Speaker 2: And it doesn't make sense to take forty years old
- 21:49Speaker 2: and do the study and finish it in forty years
- 21:53Speaker 2: to ever result. It's but the FDA is working with
- 21:57Speaker 2: us on trying to get other indications that don't take
- 22:03Speaker 2: so long to.
- 22:06Speaker 1: How long, how long and how big would that study
- 22:08Speaker 1: need to be to be properly powered.
- 22:11Speaker 2: We had three thousand people for four years.
- 22:14Speaker 1: That was the design.
- 22:15Speaker 2: Yeah.
- 22:15Speaker 1: And it's just hard to fund because this is a
- 22:17Speaker 1: generic drug. It's cheap, which is good if you want
- 22:20Speaker 1: to take it, but it's bad because there's no drug
- 22:22Speaker 1: company that can make a billion dollar selling it, so
- 22:24Speaker 1: they're not going to pay for the trial.
- 22:26Speaker 2: Right, And we had funding, and then there was COVID
- 22:29Speaker 2: and then we lost, you know, the funding.
- 22:34Speaker 1: Tell me about supplements.
- 22:37Speaker 2: I'll start with a good thing. Supplements are good for
- 22:39Speaker 2: the economy.
- 22:41Speaker 1: Yeah, okay, because people spend a lot of money on them. Yes,
- 22:44Speaker 1: you know.
- 22:44Speaker 2: For me, supplement means that you measured something and it's
- 22:49Speaker 2: slow and you give it back, right, But that's not
- 22:52Speaker 2: how supplements are done. Supplements are pecking together one hundred
- 22:56Speaker 2: things or several things and giving you an also in
- 22:59Speaker 2: the bottle they say take two. Okay. There's no clinical
- 23:04Speaker 2: data on supplements. Okay. The FDA approves supplement not based
- 23:08Speaker 2: on clinical data. So what marketing of supplement is a
- 23:14Speaker 2: total hope? Okay, there's no promise. Not only that, the
- 23:19Speaker 2: most dangerous things is multi supplement that you take them together. Okay,
- 23:25Speaker 2: and you think they're additive, but they're antagonistic many times,
- 23:29Speaker 2: because if they're biologically important, you're going to find interactions
- 23:33Speaker 2: that you don't like. We actually know that people who
- 23:36Speaker 2: take multi supplements have increased mortality in spite of the
- 23:40Speaker 2: fact that they are the people who also exercise and
- 23:43Speaker 2: diet very often.
- 23:44Speaker 1: When you say multi supplement, like a multi vitamin or
- 23:47Speaker 1: what do you.
- 23:47Speaker 2: Mean like multi vitamins, let me ask.
- 23:52Speaker 1: You another question. So the field that you are in
- 23:59Speaker 1: is full of and has always for all of history
- 24:01Speaker 1: been full of cranks and charlatan's. You're a doctor at
- 24:05Speaker 1: a medical school, Like, how do you deal with that?
- 24:09Speaker 1: And do your colleagues think you are a crank and
- 24:10Speaker 1: a charlatan?
- 24:11Speaker 2: Respectfully, what you said was exactly the sentiment when I
- 24:15Speaker 2: got several major organizations to meet in New York and say, hey,
- 24:20Speaker 2: we have a lot of progress, and we have a
- 24:22Speaker 2: lot of noise.
- 24:23Speaker 1: When was this? When was this?
- 24:25Speaker 2: That was two years ago? Two years ago, and we
- 24:27Speaker 2: did something that's so unusual for a bunch of scientists.
- 24:31Speaker 2: We said, you know what, we really don't know what
- 24:35Speaker 2: to do. Why don't we take a branding company and
- 24:39Speaker 2: let them deal with it? And this is the best
- 24:42Speaker 2: thing we did because the branding company actually worked. It
- 24:45Speaker 2: was hundreds of thousands of dollars and we're still working
- 24:48Speaker 2: with them.
- 24:49Speaker 1: It makes me nervous when you say branding company. I'm
- 24:52Speaker 1: asking you about cracks, Charlotte. Since you start telling me
- 24:55Speaker 1: about branding, it makes me nervous.
- 24:56Speaker 2: But I think I'll make you I'll make you feel better.
- 25:00Speaker 2: And they said, first of all, you're using thirty different
- 25:05Speaker 2: terms to describe yourself. Yeah, okay, help spend, launch, avity, rejuvenation, gerontology, immortality,
- 25:13Speaker 2: you know, goes on and on, and that's very divisive.
- 25:17Speaker 2: So they said, hey, this is a problem. Second, they said, yeah,
- 25:21Speaker 2: you have an enemy and that's the noise. Okay, and
- 25:26Speaker 2: that's a good thing. Okay, that's a good thing because
- 25:29Speaker 2: you want to distinct yourself from the noise. The noise
- 25:33Speaker 2: are Charlotte Tan's snake oil, Brian Johnson, you know, things
- 25:39Speaker 2: like that. And they said, and for you, the best
- 25:42Speaker 2: name is gero science. And we said, oh, we like geroscience.
- 25:47Speaker 2: We always called ourselves gero scientists. But you know what,
- 25:51Speaker 2: gero scientists didn't pick up them. They said, yeah, because
- 25:53Speaker 2: you never marketed it. It's not even in a Wikipedia.
- 25:58Speaker 2: So we so with this branding company, we do several things.
- 26:03Speaker 2: First of all, like what we do now I talk
- 26:05Speaker 2: about geroscience. We changed the Academy that was the Academy
- 26:08Speaker 2: of Health and Lifespan Research to Academy of Geroscience, my
- 26:12Speaker 2: center that was the Insuite for Aging Research and the
- 26:14Speaker 2: Institute of Geroscience. We have a geoscience web now that
- 26:19Speaker 2: will feed all the organizations and all the people who
- 26:22Speaker 2: want to know everything. And we want to make it,
- 26:25Speaker 2: you know, like a real thing and not a divisive
- 26:29Speaker 2: thing or really distinct ourselves from from the noise.
- 26:33Speaker 1: And in a sentence, what is geroscience?
- 26:38Speaker 2: So the ideal of geroscience is that we target We
- 26:41Speaker 2: can target aging by by learning the science and improve
- 26:49Speaker 2: basically decrease the burden of diseases and increase increase the
- 26:54Speaker 2: health spen for everyone.
- 26:59Speaker 1: Is there a Wikipedia page?
- 27:02Speaker 2: Not yet?
- 27:02Speaker 1: No, no, you can make a Wikipedia page.
- 27:04Speaker 2: No no, no, no no, no, there will be soon.
- 27:09Speaker 2: But it's actually a process you can make. You can
- 27:12Speaker 2: make the Wikipedia page. But when it comes to things
- 27:15Speaker 2: like that, there's a committee and the committee now is
- 27:18Speaker 2: biased and we're spending actually twenty thousand dollars to show
- 27:22Speaker 2: the gero science is a real.
- 27:25Speaker 1: Say, convinced the Wikipedia committee. Yeah, wow, Like, do you
- 27:30Speaker 1: need a newspaper reporter to use the word in the
- 27:33Speaker 1: in the you know, in the Wall Street Journal, in
- 27:35Speaker 1: the New York Times? That is that what you need.
- 27:37Speaker 2: But it was effective because when I called ourselves gero science,
- 27:41Speaker 2: when I talked about it, several editors have changed the
- 27:44Speaker 2: name of the article to anti aging because they said,
- 27:47Speaker 2: we don't know what's gero science, but anti aging.
- 27:50Speaker 1: What do you think about the phrase anti aging?
- 27:53Speaker 2: So first of all, we're not anti the aging, but
- 27:57Speaker 2: it is used much more commonly for non scientific fact
- 28:03Speaker 2: than for science. And so we actually we we actually
- 28:09Speaker 2: trying to make it worse, really for people to know
- 28:11Speaker 2: that whoever called themselves anti aging and there's no gero
- 28:15Speaker 2: signs behind that. Yeah, it's going to be bad.
- 28:23Speaker 1: We'll be back in a minute with the lightning round. Okay,
- 28:36Speaker 1: let's finish with a lightning round a little bit more random.
- 28:43Speaker 1: What one thing you do, even though it may shorten
- 28:46Speaker 1: your life.
- 28:49Speaker 2: So I'm doing the sixteen hour fast, but I'm a foodie. Okay,
- 28:56Speaker 2: so after the sixteen hours fast, I really don't care
- 29:00Speaker 2: what I got interesting?
- 29:03Speaker 1: What was the last really unhealthy but delicious thing that
- 29:06Speaker 1: you ate?
- 29:09Speaker 2: Black forest cake? I have a black forest cake, also
- 29:15Speaker 2: with ice cream.
- 29:16Speaker 1: Yes, ice cream is so good. Do you have a
- 29:20Speaker 1: favorite really really old person, like from the Old Testament
- 29:25Speaker 1: or from mythology.
- 29:29Speaker 2: I'm talking about Metusilla because he supposedly leave nine hundred
- 29:36Speaker 2: and sixty nine years And the people who are very
- 29:41Speaker 2: orthodox in religions, whether Christians or Jews, believe every word
- 29:47Speaker 2: in the Bible, right, But when you ask them, did
- 29:49Speaker 2: Metusla leave nine hundred and sixty nine years? Ah, they
- 29:52Speaker 2: didn't know how to count.
- 29:55Speaker 1: Well, I don't know that particular story. I mean one
- 29:58Speaker 1: thing that's interesting to me, Like in the Old Testament,
- 30:00Speaker 1: people are just old. Noah's hundreds of years old, whatever.
- 30:03Speaker 1: But you know, the myths and the stories that focus
- 30:06Speaker 1: in particular on in more mentality especially, it's often bad, right,
- 30:12Speaker 1: somebody lives forever and it's terrible to live forever, which
- 30:16Speaker 1: is interesting in the context of this conversation.
- 30:20Speaker 2: Right, And you know, there's a whole people who are immortalists,
- 30:25Speaker 2: and that's very different from me. Okay, I'm not immortalist.
- 30:29Speaker 2: In fact, I'm saying what to live a billion more years?
- 30:33Speaker 2: How many you know, presidents do you have to suffer through? Yeah,
- 30:38Speaker 2: I'm tired a little bit. Immortality. Immortality is a belief,
- 30:44Speaker 2: and people realize now that this is not going to
- 30:48Speaker 2: happen in their lifetime, and what they are turning into
- 30:52Speaker 2: is freezing.
- 30:53Speaker 1: Yeah, that's been around for a while. Cryogenics like cryogenous
- 30:57Speaker 1: that one seems very crankish to me.
- 31:00Speaker 2: Well, but it relieves them in their mind they're dealing
- 31:04Speaker 2: with their immortality.
- 31:06Speaker 1: So I read this interview with you where you talked
- 31:08Speaker 1: about the fact that people with Alzheimer's disease sometimes will
- 31:13Speaker 1: respond to music that they know from earlier in their life,
- 31:16Speaker 1: and that you actually started making an Alzheimer's playlist for yourself.
- 31:21Speaker 1: What's on the playlist?
- 31:23Speaker 2: So usually the playlist for those people are of their
- 31:28Speaker 2: most earlier memories as young adults, right when you were
- 31:33Speaker 2: kind of a kid, when you were in high school,
- 31:36Speaker 2: when you were in college. And so for me, it's
- 31:40Speaker 2: really the sixties seventies.
- 31:41Speaker 1: It's a great era. It's my favorite era.
- 31:44Speaker 2: In a lot of ways that are taking and my
- 31:47Speaker 2: kids are saying, you know, when you have Alzheimer's, mom
- 31:50Speaker 2: would leave you, not because she doesn't like you, but
- 31:54Speaker 2: because she wouldn't stand the music.
- 31:58Speaker 1: So, from your work with people who've lived past one hundred,
- 32:01Speaker 1: I'm curious, what's one thing that you've learned that's not
- 32:05Speaker 1: related to health.
- 32:08Speaker 2: Will they have a belief in what makes them leave
- 32:15Speaker 2: two hundred? And they could adopt the belief because they
- 32:18Speaker 2: actually had genes, which means they were protected from everyone.
- 32:21Speaker 1: What actually made them lift two hundred is their genes,
- 32:23Speaker 1: not the fact that they play golf every Wednesday or whatever.
- 32:27Speaker 2: So I have a woman who died at the age
- 32:31Speaker 2: one hundred and ten, and she smoked for ninety five years,
- 32:34Speaker 2: and she thinks it's because of cigarettes. She said, the
- 32:38Speaker 2: four doctors that told her to stop smoking, they died.
- 32:41Speaker 1: Yes, yes, Okay. Of all the things we've talked about,
- 32:46Speaker 1: If there's only one thing I do to live a longer,
- 32:49Speaker 1: healthier life, what should I do?
- 32:52Speaker 2: You know? I think at the end it's all individualized.
- 32:55Speaker 2: Will be able to see what is the one thing
- 32:58Speaker 2: you do. Look, I'm looking at you. It looks to
- 33:01Speaker 2: me like that your BMI is normal. It looks to
- 33:04Speaker 2: me that you're probably exercising. So I don't know, you
- 33:08Speaker 2: have to tell me what you don't do, and I'll
- 33:12Speaker 2: pick one.
- 33:12Speaker 1: Yeah, that's really because I was hoping you'd say exercise,
- 33:15Speaker 1: because I was like, oh, yeah, that's the what I got.
- 33:18Speaker 1: I'm not a great sleeper. I don't know, you know,
- 33:22Speaker 1: I don't look at my phone. Whatever I do the
- 33:23Speaker 1: things they say to do, I just don't tend to
- 33:25Speaker 1: sleep that well.
- 33:27Speaker 2: So with sleep, there there are two things. One is
- 33:31Speaker 2: for the young people and one is for the old.
- 33:33Speaker 2: For the young people, stop bingch watching. Okay, a lot
- 33:37Speaker 2: of the sleep deprivation is self inflicted. Right, you need
- 33:43Speaker 2: eight hours. You should strive for eight hours sleep, and
- 33:47Speaker 2: so that means that you have to plan which are
- 33:49Speaker 2: the eight hours for the older one or older one
- 33:53Speaker 2: than young. So for you and me, it's eight hours
- 33:58Speaker 2: in a dark room without electronic Okay, you're not going
- 34:04Speaker 2: to sleep the eight hours I sleep for some reason,
- 34:08Speaker 2: no matter what happen. I travel around the world. I'm
- 34:10Speaker 2: just like, I sleep six hours and forty minutes no
- 34:13Speaker 2: matter what. But if I sleep less, it's not going
- 34:18Speaker 2: to be good. But what I'm doing that's different than you.
- 34:21Speaker 2: I have a feet, bit, you can have a ring,
- 34:25Speaker 2: and you can actually measure because it's possible that you'll
- 34:28Speaker 2: find that your ram sleep and deep sleep are long
- 34:32Speaker 2: enough and you don't need the sleep, and you're not
- 34:35Speaker 2: going to feel tired, even if you feel that you
- 34:37Speaker 2: didn't sleep well.
- 34:39Speaker 1: So you're saying it's important to be in bed in
- 34:43Speaker 1: the dark for eight hours, but it's okay to not
- 34:45Speaker 1: sleep the whole time. Right, So do you lie in
- 34:48Speaker 1: bed for an hour and twenty minutes every night not sleeping?
- 34:53Speaker 2: That's pretty much what happens. I'm spending time trying to
- 34:58Speaker 2: fall asleep and trying to stay asleep.
- 35:00Speaker 1: Yes, anything else we should talk about, just.
- 35:05Speaker 2: The one thing that's important to know that aging, that
- 35:08Speaker 2: what what we're doing is not only for older adults.
- 35:11Speaker 2: People who survive cancer are aging rapidly because we give
- 35:15Speaker 2: them chemotherapy and radiation. Right. I don't know if you
- 35:19Speaker 2: know cancer survivors, but they usually are doing badly after
- 35:22Speaker 2: they recover, so they need help. People with HIV have
- 35:28Speaker 2: diseases ten years younger than their ages. Down syndrome is
- 35:32Speaker 2: an aging syndrome. Disabled people, you know, need help. And
- 35:37Speaker 2: if we're going to Mars, if this is for some people,
- 35:40Speaker 2: it's very important. I think this world is beautiful we
- 35:44Speaker 2: need to repair it. But if you go to Mars,
- 35:46Speaker 2: you're not going to get there before we stopped aging,
- 35:50Speaker 2: because you'll be sick on the way there and you're
- 35:53Speaker 2: never coming back.
- 35:55Speaker 1: Thank you very much for your time. I really appreciate it.
- 35:58Speaker 2: Thank you very much.
- 36:06Speaker 1: Your Barselai is a physician and he runs it's the
- 36:09Speaker 1: Institute for Geroscience at the Albert Einstein College of Medicine.
- 36:14Speaker 1: Just a quick note, we're going to be taking the
- 36:15Speaker 1: next couple weeks off. We're going to be back after
- 36:17Speaker 1: that with more episodes of What's Your Problem. Please email
- 36:20Speaker 1: us at problem at pushkin dot fm. Tell us what
- 36:23Speaker 1: kinds of shows we should do more of or less
- 36:25Speaker 1: of our particular people you think would be good on
- 36:27Speaker 1: the show. You can also find me on x and
- 36:29Speaker 1: on LinkedIn. Our show is produced by Gabriel Hunter Chang
- 36:33Speaker 1: and Trina Menino. Our editor is Lydia Jane Kott, and
- 36:36Speaker 1: our engineer is Sarah Buguer. I'm Jacob Goldstein.